Benzinga | Dec 10, 2020 08:12AM EST

Establishment Labs Completes 21 Motiva Mia Patients In IRB Approved Study In Costa Rica

* IRB Approval Includes Both the Ergonomix2 Diamond Implant and Mia Tools

SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia(r) system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond(r) breast implant, and has completed the procedure in the first 21 patients in the study.